AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.
Author archives: Kinjel Shah
Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks
Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.
5 Low Price-to-Book Value Stocks to Buy as 2022 Nears
The P/B ratio helps identify low-priced stocks with high-growth prospects. ASE Technology Holding (ASX), Signet Jewelers Limited (SIG), Celestica (CLS), DXC Technology Company (DXC) and Atlas Corp. (ATCO) are some…
Pharma Stock Roundup: AZN, BAYRY Q3 Results, PFE COVID Pill’s Strong Efficacy
AstraZeneca (AZN) and Bayer (BAYRY) announce Q3 results. Pfizer’s (PFE) COVID-19 pill reduces hospitalizations and deaths substantially.
Vaccine Stocks Down Following Merck’s COVID-19 Pill Success
Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19
Pharma Stock Roundup: ABBV’s Deal With RGNX, LLY COVID Drug’s Government Order Win
AbbVie (ABBV) buys rights to Regenexbio’s gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-1…
Pharma Stock Roundup: PFE’s COVID Jab Full Approval by FDA, JNJ’s Booster Data
FDA approves Pfizer’s (PFE) BLA for COVID-19 vaccine, Comirnaty. J&J (JNJ) released data supporting use of the booster shot.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for th…